Mean (SD) | SO2 (per 10 μg/m3)a | SO2 levels > 125 SO2 μg/m3 | |||||
---|---|---|---|---|---|---|---|
% | 95% CI | % | 95% CI | ||||
Anti-asthma medication | |||||||
Short-acting β-agonist (R03A) | 88 (47.2) | 1.09% | 0.49% | 1.70% | 13.7% | 4.5% | 23.7% |
Long-acting (R03B) | 38.7 (21.4) | 0.74% | −0.03% | 1.52% | 8.7% | −2.2% | 20.7% |
Primary care MD visits (PCMD) | |||||||
Respiratory infections (J0-J2) | 108.6 (46.2) | 1.12 | 0.54% | 1.71% | 15.8% | 7.2% | 25.1% |
Asthma and COPD (J44–45) | 15.6 (9.6) | 2.08% | 1.13% | 3.04% | 28.4% | 12.8% | 46.2% |
Hospital emergency department visits (HED) | |||||||
Respiratory infections (J0-J2) | 9.3 (4.3) | 1.09% | −0.22% | 2.41% | 7.9% | −60.9% | 27.8% |
Asthma and COPD (J44–45) | 4.3 (2.7) | 0.95% | −0.99% | 2.93% | 3.3% | −19.8% | 33.2% |